CATEGORY: HEART & CIRCULATION
A daily aspirin has been the default lifelong pill for people with coronary artery disease for decades. Clopidogrel beat it. Among adults whose heart arteries are already narrowed by plaque, long-term clopidogrel lowered the combined risk of heart attack, stroke, cardiovascular death and related events by 14% compared with daily aspirin, at 2.61 against 2.99 events per 100 patient-years, with no increase in major bleeding.1 The finding comes from a pooled analysis of individual patient records from seven randomized trials totaling 28,982 people, published in The Lancet.
Seven Trials, Read Patient by Patient
To test whether clopidogrel is really the better choice, researchers gathered the raw, person-by-person records of every randomized trial that had put clopidogrel alone up against aspirin alone in this population. Seven qualified, from the landmark CAPRIE study of the 1990s to the large Korean HOST-EXAM trial, and the team reanalyzed them as one dataset. Chance, not a physician, had sorted each of the 28,982 patients to one drug or the other. That is why the two groups started out alike in age, health and habits, and why any gap at the end belongs to the drugs. Follow-up ran a median of 2.3 years and as long as five and a half, with heart attacks, strokes, cardiovascular deaths and bleeding episodes recorded and verified inside each trial. Results are counted per 100 patient-years, a measure that adds up every participant’s time in the study so that people followed for one year and for five both count fairly.
Fewer Heart Attacks and Strokes, and No Extra Bleeding
Major cardiovascular or cerebrovascular events, meaning heart attack, stroke, cardiovascular death and related emergencies, occurred 929 times on clopidogrel and 1,062 times on aspirin. That is 2.61 against 2.99 events per 100 patient-years, a 14% lower risk, and it was driven by roughly 20% fewer heart attacks and strokes. Bleeding is the main worry with any clot-preventing drug. Here the two were even: 0.71 events per 100 patient-years on clopidogrel and 0.77 on aspirin, a difference small enough to be chance. One thing did not move. Deaths from any cause were the same in both groups over the period studied.
Two Different Doors on the Same Sticky Cell
Both drugs act on platelets, the tiny cell fragments in blood that clump together to plug a damaged vessel wall and that can also clump inside a narrowed artery, setting off a heart attack or stroke. Aspirin and clopidogrel quiet the same cell through two different doors. Aspirin blocks one chemical signal that tells platelets to activate. Clopidogrel blocks another, a receptor sitting on the platelet’s surface. A long-noted wrinkle is that some people carry gene variants that slow the body’s conversion of clopidogrel into its active form. The advantage held across subgroups here, including patients with reduced clopidogrel responsiveness.
A Result That Leans Against a Long-Standing Default
The authors concluded that their findings support considering clopidogrel as the preferred long-term antiplatelet strategy instead of aspirin for people with established coronary artery disease. Both medicines are decades old, generic and cheap. This is not a new drug against an old one, but two familiar pills whose head-to-head answer took thirty years of trials to accumulate. The individual trials pooled here had each pointed the same way, and combining their patients gave the question its most precise answer yet.
Key Takeaways
- Across seven randomized trials of 28,982 adults with coronary artery disease, clopidogrel lowered the combined rate of heart attack, stroke and other major cardiovascular events by 14% against daily aspirin: 2.61 versus 2.99 events per 100 patient-years.
- The benefit came from fewer heart attacks and strokes. Deaths from any cause were the same on both drugs, and major bleeding was no more common on clopidogrel.
- The advantage held even among patients whose genetic makeup slows clopidogrel’s activation.
References
- Valgimigli M, Choi KH, Giacoppo D, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. The Lancet. 2025;406(10508):1091–1102. link